Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Enrica Antonia Martino, Daniele Derudas, Elena Rossi, Sofia Terlizzi, Giovanni Reddiconto, Paola Stefanoni, Jacopo Micozzi, Silvia Mangiacavalli, Elena Zamagni, Massimo Offidani, Anna Furlan, Gabriele Buda, Sr., Flavia Lotti, Carmine Liberatore, Antonio Lazzaro, Roberta Della Pepa, Giuseppe Bertuglia, Emiliano Barbieri, Concetta Conticello, Claudio De Magistris, Lorenzo De Paoli, Velia Bongarzoni, Anna Maria Cafro, Anna Mele, Pietro Benvenuti, Claudio Cerchione, Cirino Botta, Elisabetta Antonioli, Nicola Sgherza, Sara Aquino, Giuseppe Mele, Gregorio Barila, Salvatore Palmieri, Ombretta Annibali, Rosario Bianco, Massimiliano Arangio Febbo, Gloria Margiotta Casaluci, Angela Rago, Raffaele Fontana, Francesca Farina, Ernesto Vigna, Antonella Bruzzese, Catello Califano, Angela Amendola, Daniela Roccotelli, Alessandra Lombardo, Annalisa Citro, Giuseppina Uccello, Renato Zambello, Alessandro Maggi, Santo Neri, Michele Monachesi, Alessandro Gozzetti, Vittorio Montefusco, Marino Brunori, Nicola Di Renzo, Marta Coscia, Valerio De Stefano, Antonino Neri, Francesco Di Raimondo, Fortunato Morabito, Pellegrino Musto, Massimo Gentile

Blood (2024) 144 (Supplement 1): 4699.

https://doi.org/10.1182/blood-2024-206008

Published: 2024

Journal Articles

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

Blood (2023) 142 (Supplement 1): 2018.

https://doi.org/10.1182/blood-2023-177945

Published: 2023

Journal Articles

OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses

Paul G. Richardson, Fredrik H. Schjesvold, Haifaa Abdulhaq, Daniel Coriu, Antonio Lazzaro, Pieter Sonneveld, Torbjörn Kullenburg, Johan Harmenberg, Marcus Thuresson, Catriona Byrne, María-Victoria Mateos

Blood (2021) 138 (Supplement 1): 2732.

https://doi.org/10.1182/blood-2021-146863

Published: 2021

Journal Articles

Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines

Philippe Moreau, A Keith Stewart, MB, ChB, Antonio Lazzaro, Meletios A Dimopoulos, MD, Michele Cavo, MD, Sikander Ailawadhi, Karim Iskander, Mei Huang, Anita Zahlten-Kumeli, Maria-Victoria Mateos, MD PhD

Blood (2018) 132 (Supplement 1): 3244.

https://doi.org/10.1182/blood-2018-99-114863

Published: 2018

Journal Articles

Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis

Blood (2016) 128 (22): 5464.

https://doi.org/10.1182/blood.V128.22.5464.5464

Published: 2016

Journal Articles

Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in Italy: A Subanalysis of the Stratus Trial (MM-010)

Michele Cavo, Paolo Corradini, Francesco Di Raimondo, Mario Petrini, Anna Maria Cafro, Tommaso Caravita di Toritto, Massimo Offidani, Gianpietro Semenzato, Renato Zambello, Antonio Lazzaro, Maria Teresa Petrucci, Francesco Rodeghiero, Mathew Simcock, Ana Slaughter, Jennifer Herring, Teresa Peluso, Antonio Palumbo

Blood (2015) 126 (23): 5376.

https://doi.org/10.1182/blood.V126.23.5376.5376

Published: 2015

Journal Articles

Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

Annamaria Brioli, MD, Annalisa Pezzi, Statistician, Daniele Derudas, MD, Maria Concetta Petti, MD, Beatrice Anna Zannetti, MD, Felicetto Ferrara, MD, Serena Rocchi, MD, Francesco Nobile, MD, Anna Baraldi, MD, Pellegrino Musto, MD, Francesco Lanza, MD, Katia Mancuso, MD, Letizia Canepa, MD, Lucio Catalano, MD, Antonio Lazzaro, MD, Graziella Pinotti, MD, Mario Boccadoro, MD, Michele Cavo, MD

Blood (2014) 124 (21): 1182.

https://doi.org/10.1182/blood.V124.21.1182.1182

Published: 2014

Journal Articles

Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

Stefano Sacchi, MD, Samantha Pozzi, MD, Marina Cesaretti, Luigi Marcheselli, MS, Gabriele Buda, MD, Antonio Lazzaro, MD, Luca Baldini, Francesco Di Raimondo, MD, Pellegrino Musto, MD, Alfonso Zaccaria, Giorgina Specchia, Umberto Vitolo, MD, Massimo Magagnoli, MD, Franco Silvestris, MD, Pier Paolo Fattori, MD, Patrizia Tosi, MD, Eliana Valentina Liardo, MD, Alessia Bari, MD, Angelo Michele Carella

Blood (2013) 122 (21): 4383.

https://doi.org/10.1182/blood.V122.21.4383.4383

Published: 2013

Journal Articles

A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple Myeloma

Stefano Sacchi, Samantha Pozzi, Stefania Badiali, Attilio Guarini, Carla Mazzone, Alessandro Corso, Donatella Vincelli, Luciano Masini, Pellegrino Musto, Roberto Ria, Giovanni Quarta, Antonio Lazzaro, Antonio Palumbo, Fortunato Morabito

Blood (2012) 120 (21): 1851.

https://doi.org/10.1182/blood.V120.21.1851.1851

Published: 2012

Journal Articles

Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL)

Stefano Sacchi, Samantha Pozzi, Marina Cesaretti, Luigi Marcheselli, Eliana Valentina Liardo, Gabriele Buda, Antonio Lazzaro, Luca Baldini, Francesco Di Raimondo, MD, Pellegrino Musto, Alfonso Zaccaria, Giorgina Specchia, Umberto Vitolo, Massimo Magagnoli, Franco Silvestris, Pier Paolo Fattori, Patrizia Tosi, Angelo Michele Carella

Blood (2012) 120 (21): 1645.

https://doi.org/10.1182/blood.V120.21.1645.1645

Published: 2012

Journal Articles

Ten Year-Long Term Survival After up-Front Autologous Stem Cell Transplantation in Multiple Myeloma: Results From Two Prospective Clinical Trials

Blood (2012) 120 (21): 594.

https://doi.org/10.1182/blood.V120.21.594.594

Published: 2012

Journal Articles

Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)

Blood (2011) 118 (21): 1821.

https://doi.org/10.1182/blood.V118.21.1821.1821

Published: 2011

Journal Articles

Phase II Study of Velcade® Plus Mabthera® In Relapsed Follicular Lymphomas

Stefano Sacchi, Raffaella Marcheselli, Alessia Bari, Eliana Valentina Liardo, Stefano Luminari, Francesco Merli, Antonio Lazzaro, Santo Neri, Angelo Michele Carella, Alberto Fragasso, Simona Falorio, Gabriele Buda, Pellegrino Musto, MD, Matteo Dell’Olio, Luca Baldini

Blood (2010) 116 (21): 1801.

https://doi.org/10.1182/blood.V116.21.1801.1801

Published: 2010

Journal Articles

Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients.

Stefano Sacchi, MD, Luigi Marcheselli, Samantha Pozzi, Alessia Bari, Stefano Luminari, Fiorella Ilariucci, Caterina Stelitano, Francesco Angrilli, Antonio Lazzaro, Luca Baldini, Mauro Spriano, Giuseppe Caparrotti, Maurizio Musso, Giovanni Quarta, Maura Brugiatelli

Blood (2008) 112 (11): 1012.

https://doi.org/10.1182/blood.V112.11.1012.1012

Published: 2008

Journal Articles

Autologous Bone-Marrow Stem Cell Support in Acute Anterior Myocardial Infarction.

Daniele Vallisa, MD, Massimo Piepoli, M.D., Luigi Cavanna, M.D., Cristina Arbasi, M.D., Carlo Moroni, M.D., Antonio Lazzaro, M.D., Alessandro Capucci, M.D., Patrizia Bernuzzi, M.D., AnnaLisa Arcari, M.D., Costanza Bosi, M.D.

Blood (2007) 110 (11): 3692.

https://doi.org/10.1182/blood.V110.11.3692.3692

Published: 2007

Journal Articles

Imatinib-Related Neutropenia in Chronic-Phase Chronic Myelogenous Leukaemia: Safety and Efficacy of Granulocyte-Colony-Stimulating Factor (Filgrastim) Use.

Antonio Lazzaro, MD, Patrizia Bernuzzi, MD, Elena Trabacchi, MD, Daniele Vallisa, MD, Annalisa Arcari, MD, Raffaella Bertè, MD, Carlo F. Moroni, MD, Elisa Anselmi, MD, Luigi Cavanna, MD

Blood (2005) 106 (11): 4864.

https://doi.org/10.1182/blood.V106.11.4864.4864

Published: 2005

Journal Articles

The Role of Antiviral Treatment in Hepatitis C Virus (HCV)-Related Non-Hodgkin Lymphoma: An Update of a Multicenter Study.

Daniele Vallisa, MD, Patrizia Bernuzzi, MD, Luca Arcaini, MD, Antonio Lazzaro, MD, Elena Trabacchi, MD, Elisa Anselmi, MD, Anna Lisa Arcari, MD, Carlo Moroni, MD, Raffaella Berte, MD, Alessandro Malingher, MD, Mario Lazzarino, MD, Luigi Cavanna, MD

Blood (2005) 106 (11): 1509.

https://doi.org/10.1182/blood.V106.11.1509.1509

Published: 2005

NARROW

Isatuximab, Pomalidomide, and Dexamethasone (IsaPd) As Salvage Therapy for Patients with Multiple Myeloma: Multicenter, Retrospective Clinical Experience with 262 Cases Outside of Controlled Clinical Trials

Long-Term Outcomes from the Phase 3 OCEAN (OP-103) Study: Melflufen and Dexamethasone (Dex) Versus Pomalidomide (Pom) and Dex in Relapsed Refractory Multiple Myeloma (RRMM)

OCEAN (OP-103): Melflufen/Dexamethasone (Dex) Compared with Pomalidomide (Pom)/Dex in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) - Safety and Tolerability Analyses

Efficacy and Safety of Once-Weekly vs Twice-Weekly Carfilzomib Plus Dexamethasone: Subgroup Analysis of the Phase 3 A.R.R.O.W. Study (NCT02412878) By Prior Lines

Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis

Safety and Efficacy of Pomalidomide Plus Low-Dose Dexamethasone (POM + LoDEX) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in Italy: A Subanalysis of the Stratus Trial (MM-010)

Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM

Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma

A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple Myeloma

Results of a Phase II Study of Lenalidomide in Combination with Rituximab for the Treatment of Indolent Non Follicular Non Hodgkin Lymphoma (NHL)

Ten Year-Long Term Survival After up-Front Autologous Stem Cell Transplantation in Multiple Myeloma: Results From Two Prospective Clinical Trials

Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD)

Phase II Study of Velcade® Plus Mabthera® In Relapsed Follicular Lymphomas

Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients.

Autologous Bone-Marrow Stem Cell Support in Acute Anterior Myocardial Infarction.

Imatinib-Related Neutropenia in Chronic-Phase Chronic Myelogenous Leukaemia: Safety and Efficacy of Granulocyte-Colony-Stimulating Factor (Filgrastim) Use.

The Role of Antiviral Treatment in Hepatitis C Virus (HCV)-Related Non-Hodgkin Lymphoma: An Update of a Multicenter Study.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only